{"filings":[{"id":2108198,"accession_number":"0001104659-26-092128","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-08-06T21:15:10+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclaris Therapeutics enters into new at-the-market equity offering agreement with Leerink and Cantor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amended and Restated Sales Agreement with Leerink Partners and Cantor Fitzgerald for at-the-market common stock offerings.","Commission of 3.0% of gross proceeds payable to agents; no minimum offering amount required.","Replaces prior $100M ATM agreement dated February 27, 2025; new agreement has no stated maximum.","Shares sold under existing Form S-3 registration statement; Company retains discretion on timing and size."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2088203,"accession_number":"0001104659-26-091629","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-08-06T11:15:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Therapeutics Q2 2026 net loss $21.5M; cash $170.6M; ATI-052 data supports quarterly dosing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.5M in Q2 2026 vs $15.4M in Q2 2025; revenue $1.6M vs $1.8M.","Cash, equivalents and marketable securities $170.6M at June 30, 2026; subsequent ATM raised $40.2M gross from 7.3M shares.","Phase 1a SAD/MAD data for ATI-052 (anti-TSLP/IL-4Rα bispecific) shows favorable safety and potential for quarterly dosing.","Top line results expected H2 2026 from Phase 1b POC trials of ATI-052 in asthma and atopic dermatitis, and Phase 2 trial of bosakitug in AD.","Plan to initiate Phase 2b program for ATI-052 and Phase 2b trial of modzatinib in lichen planus in Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":860757,"accession_number":"0001104659-26-070494","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-06-04T20:01:13+00:00","items":["5.07"],"status":"ready","headline":"Aclaris shareholders elect directors, approve executive pay at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["80.55% of shares voted; 112,499,671 of 139,663,680 outstanding shares represented.","Elected Anand Mehra and Maxine Gowen as directors with 83.1M and 84.2M votes for, respectively.","Advisory vote on named executive officer compensation approved: 83.4M for, 9.7M against.","Ratification of PricewaterhouseCoopers as auditor passed with 112.3M votes for.","Broker non-votes of 19.4M on proposals 1 and 2; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93618,"accession_number":"0001104659-26-056669","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q1 net loss widens to $19.8M; positive Phase 1a data for ATI-052","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.8M vs $15.1M YoY; revenue $2.0M (+33%) on higher Lilly/Sun Pharma royalties.","Cash & equivalents $190.8M (up from $151.4M); raised $59.8M via 18.4M share ATM offering in March.","ATI-052 Phase 1a SAD/MAD showed half-life ~45 days, sustained target engagement up to 20 wks; supports Q3-month dosing.","Phase 1b POC trials in asthma and atopic dermatitis ongoing; top line results expected H2 2026.","Completed enrollment in bosakitug Phase 2 AD trial; results expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":1996000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93617,"accession_number":"0001104659-26-049733","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aclaris reports positive Phase 1a data for ATI-052 (half-life ~45 days) and picks lichen planus for ATI-2138","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATI-052 half-life ~45 days; complete inhibition of CCL17/TARC sustained at least 20 weeks post-dose.","Phase 1a ATI-052 well tolerated; no conjunctivitis or safety signals; dose proportional PK observed.","Phase 1b trials in asthma and atopic dermatitis enrolling; top line results expected H2 2026.","Phase 2b for ATI-052 targeting asthma planned for Q4 2026; Phase 2b ATI-2138 in lichen planus starts H2 2026.","ATI-2138 is a potential first-in-class oral ITK/JAK3 inhibitor addressing pathogenic T cells; no FDA-approved LP therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105397,"accession_number":"0001104659-26-026407","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Aclaris Therapeutics sells 5.7M shares for $20M gross proceeds in ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5.7M shares sold on March 10, 2026 for aggregate gross proceeds of $20.0M.","Purchasers include Frazier Life Sciences, Kalehua Capital, and Adage Capital Partners LP.","Sale under amended sales agreement with Leerink Partners and Cantor Fitzgerald dated Feb 27, 2025.","Gross proceeds of $20M implies average price per share of approximately $3.51."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105396,"accession_number":"0001104659-26-025420","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Aclaris Therapeutics raises $39.8M via ATM offering of 12.7M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 12.7 million shares for gross proceeds of $39.8M under ATM agreement from March 2-9, 2026.","Shares purchased by institutional investors including Deep Track Capital.","Sales executed by agents Leerink Partners and Cantor Fitzgerald."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105395,"accession_number":"0001104659-26-020070","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q4 net loss $19.8M; cash $151.4M; ATI-052 POC trials underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.8M in Q4 2025 vs $96.6M in Q4 2024; full year net loss $64.9M vs $132.1M.","Total revenue $1.3M in Q4 2025 vs $9.2M prior year; decrease due to 2024 Lilly milestone.","Cash, equivalents and marketable securities $151.4M as of Dec 31, 2025; cash runway into H2 2028.","Interim Phase 1a data for anti-TSLP/IL-4Rα bispecific ATI-052 support rapid advancement; Phase 1b POC trials in AD and asthma initiated.","IND filing for lead ITK inhibitor ATI-9494 expected H2 2026; ATI-2138 showed hair regrowth in alopecia model."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":7826000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105394,"accession_number":"0001104659-26-002694","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris Therapeutics files 8-K furnishing updated corporate overview; no new financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed Form 8-K on Jan. 12, 2026, updating its corporate overview presentation (Exhibit 99.1).","Presentation available on company website; no specific financial or operational changes provided in filing.","No earnings, guidance, clinical results, or other material events disclosed in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105393,"accession_number":"0001104659-26-001076","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Aclaris ATI-052 Phase 1a shows favorable safety, 26-day half-life, near-complete target inhibition at low doses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATI-052 well tolerated up to 720 mg; no serious AEs, no discontinuations, mild injection site redness.","PK profile shows at least 26-day effective half-life with dose-proportional Cmax and AUC.","At 30 mg, robust concentration-dependent inhibition of IL-4 and TSLP stimulated CCL17/TARC.","Data supports potential for up to every-3-month dosing; Phase 1b in AD and asthma to start Q1 2026.","Phase 2b in atopic dermatitis planned for H2 2026; top-line data from Phase 1b expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121678,"accession_number":"0001104659-25-107353","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Therapeutics Q3 net loss widens to $14.6M; cash $167.2M; pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.6M in Q3 2025 vs $7.6M in Q3 2024; total revenue $3.3M vs $4.3M.","Cash, equivalents and marketable securities $167.2M as of Sep 30, 2025, funding into H2 2028.","Positive Phase 2a results for ATI-2138 in AD; Phase 2 trial in additional indication expected H1 2026.","Top line results for bosakitug (Phase 2 AD) expected H2 2026; ATI-052 Phase 1b POC in asthma/AD expected H1 2026.","R&D expenses rose to $13.0M (vs $6.0M) driven by clinical and preclinical activities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":6531000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121677,"accession_number":"0001104659-25-098991","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris holds R&D Day presenting I&I pipeline; no specific data disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["R&D Day held Oct 14, 2025, focusing on immunology and inflammation (I&I) therapeutic franchises.","Presentation furnished as Exhibit 99.1; available on Investor Relations section of company website.","No financial results, clinical data, or guidance changes were included in the 8-K or exhibit snippet.","Company continues to develop pipeline for gaps in I&I diseases; no material updates provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138357,"accession_number":"0001558370-25-010640","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q2 net loss widens to $15.4M; advances ATI-2138, bosakitug, ATI-052 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.4M vs $11.0M YoY; revenue $1.8M, down 36% due to prior royalty sale.","Cash, equivalents & securities $180.9M; runway into H2 2028 without new financing.","Phase 2a ATI-2138 met primary/key secondary endpoints; confirms tolerability in moderate-to-severe AD.","Phase 2 trial of bosakitug (anti-TSLP mAb) in AD dosing; top line expected H2 2026.","Roland Kolbeck appointed CSO replacing Joe Monahan (planned retirement through Q1 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":3232000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138356,"accession_number":"0001558370-25-009739","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aclaris ATI-2138 Phase 2a AD trial meets primary and key secondary endpoints; 60.5% mean EASI improvement at week 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["14 patients enrolled; 10 per protocol; no SAEs or discontinuations; well tolerated with mild, transient TRAEs.","Mean EASI improvement 60.5% (77.1% excluding one outlier); 62.5% achieved ≥4-point itch reduction at week 12.","PD data show near-complete ITK target occupancy and downregulation of Th2, Th1/Th17, and fibrosis markers.","Company plans to further develop ATI-2138 in alopecia areata and explore other indications.","Preclinical work ongoing for next-gen ITK inhibitors; new INDs expected starting 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155806,"accession_number":"0001558370-25-008984","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris Therapeutics posts updated corporate presentation; no material changes discernible","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation includes corporate strategy and pipeline overview; no financial results or guidance changes disclosed.","No other material events or financial updates reported in the 8-K filing.","The presentation is available on the company's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155805,"accession_number":"0001558370-25-008430","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Aclaris shareholders approve doubling authorized shares to 400M and new equity plan with 25.6M reserve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 200M to 400M via Certificate of Amendment effective June 5, 2025; approved by ~96% of votes.","2025 Equity Incentive Plan approved with 25,556,247 share reserve (9M new shares plus rollover from prior plan).","Directors elected: Neal Walker (71.9M for), Andrew Schiff (71.7M for), William Humphries (56.7M for, 15.99M withheld).","Advisory vote on named executive officer compensation passed 55.5M to 16.98M; PwC ratified as auditor for FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155804,"accession_number":"0001558370-25-006851","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aclaris reports Q1 net loss $15.1M, cash runway extended to H1 2028; multiple pipeline milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $15.1M vs $16.9M YoY; revenue $1.5M vs $2.4M; cash $190.5M as of March 31, 2025.","Cash runway extended through first half of 2028, fully funding preclinical and clinical plans.","Bosakitug Phase 2 in atopic dermatitis to start Q2 2025; seeking partners for respiratory indications.","ATI-2138 Phase 2a AD top line results expected June 2025; ATI-052 IND cleared, Phase 1 starting Q2 2025.","Jesse W. Hall appointed CMO; Sun Pharma injunction lifted, offering potential non-dilutive financing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":1455000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174275,"accession_number":"0001558370-25-001679","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q4 net loss $96.6M, revenue $9.2M; cash $203.9M; pipeline catalysts in H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $96.6M in Q4 2024 vs $1.5M in Q4 2023; included $86.9M in-process R&D charge from bosakitug license.","Revenue $9.2M in Q4 2024 vs $17.6M in Q4 2023; full year revenue $18.7M vs $31.2M.","Cash, equivalents and marketable securities $203.9M at Dec 31, 2024; cash runway expected into 2028.","Phase 2 data from partner CTTQ in severe asthma and CRSwNP expected H1 2025; Phase 2b for bosakitug in AD enrollment H1 2025.","Leadership changes: Neal Walker named CEO; Hugh Davis appointed President and COO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":18720000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174274,"accession_number":"0001558370-25-000148","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris Therapeutics updates corporate presentation; no material new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted an updated investor presentation on January 13, 2025.","Presentation content not fully available in this filing for review.","Routine update; no earnings, pipeline, or financial guidance changes announced.","Presentation available on Aclaris website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191220,"accession_number":"0001558370-24-015838","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Aclaris licenses anti-TSLP/IL4R biologics, raises $80M, appoints Davis as President/COO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License deal: $30M upfront, $4.5M dev reimbursement, warrants for 14.3M shares at $0.00001, up to $920M milestones, royalties.","Private placement: 35.6M shares at $2.25 for $80M gross; closed Nov 19; led by Vivo Capital; cash runway into 2028.","Leadership additions: Hugh Davis as President/COO + Class III director; Steven Knapp EVP Regulatory & Quality.","Adopted 2024 Inducement Plan reserving 2M shares; Davis granted options for 375K shares, RSU for 107K shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191219,"accession_number":"0001558370-24-014522","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Therapeutics reports Q3 net loss $7.6M, improved from $29.3M YoY; cash into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.6M vs $29.3M in Q3 2023; revenue fell to $4.3M from $9.3M.","R&D expenses dropped to $6.0M from $23.9M, driven by reduced clinical and manufacturing costs.","Cash, equivalents and marketable securities of $173.4M expected to fund operations into 2028.","First patient dosed in Phase 2a trial of ATI-2138 for atopic dermatitis; top-line data expected H1 2025.","Seeking global development partner for lepzacitinib (ATI-1777) after positive Phase 2b in atopic dermatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":9509000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207683,"accession_number":"0001558370-24-011201","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q2 net loss narrows to $11.0M; cash runway extended into 2028 via $26.5M royalty sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.8M (+47% YoY) driven by higher Lilly royalties; net loss $11.0M vs $29.6M.","Cash, equivalents and securities $149.9M; July 2024 received $26.5M upfront from OLUMIANT royalty sale.","Phase 2a trial of ATI-2138 in atopic dermatitis initiated; enrollment expected in coming weeks.","Seeking global partner for lepzacitinib (ATI-1777) after positive Phase 2b top-line results.","R&D expense fell 65% to $8.8M due to completion of several clinical trials and headcount reductions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":5163000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207682,"accession_number":"0001558370-24-009853","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aclaris sells OLUMIANT royalties to OMERS for up to $31.5M upfront and milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $26.5M upfront; eligible for up to $5M additional based on 2024 sales milestones for OLUMIANT.","Sold portion of future OLUMIANT royalties from Lilly and 100% of remaining anniversary milestone payments.","Non-dilutive transaction; proceeds to strengthen balance sheet and support strategic priorities.","Aclaris continues strategic review; will invest in internal immuno-inflammatory pipeline programs.","OLUMIANT (baricitinib) is Lilly's treatment for alopecia areata; royalty term runs through remainder of license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225152,"accession_number":"0001558370-24-009009","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aclaris shareholders elect two directors, approve say-on-pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Christopher Molineaux (29.2M for, 16.2M withheld) and Vincent Milano (42.3M for, 3.1M withheld) as directors.","Advisory vote on executive compensation approved: 29.0M for, 16.3M against, 21k abstain, with 12.5M broker non-votes.","Ratified PricewaterhouseCoopers as auditor for FY2024: 56.6M for, 1.2M against, 23k abstain.","Turnout of 81.09% (57.8M of 71.3M shares outstanding) present or represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225151,"accession_number":"0001558370-24-007055","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aclaris reports Q1 net loss $16.9M, down 40% YoY; advances ATI-2138 into Phase 2a for AD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $16.9M from $28.2M YoY; total revenue $2.4M, flat.","Cash and marketable securities $161.4M at March 31, 2024; expects lower quarterly cash burn ahead.","Progressing ATI-2138 (ITK/JAK3 inhibitor) into Phase 2a proof-of-concept trial for moderate-to-severe atopic dermatitis.","Seeking global development partner for lepzacitinib (topical JAK 1/3 inhibitor) after positive Phase 2b AD data.","R&D expenses fell to $9.8M from $22.6M, driven by wind-down of programs and workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":2398000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244379,"accession_number":"0001558370-24-003572","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Aclaris directors to depart at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Andrew Powell resigns effective June 6, 2024; no disagreement cited.","Director Bryan Reasons will not stand for re-election at June 6 annual meeting; no disagreement.","No replacements announced for the two departing board members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244378,"accession_number":"0001558370-24-001752","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q4 net loss improves to $1.5M on $17.6M revenue; cash down to $181.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.5M vs $27.6M YoY; revenue $17.6M vs $7.8M driven by Sun Pharma upfront payment.","Full-year net loss $88.5M; cash & securities $181.9M (Dec 2023) vs $229.8M (Dec 2022).","Impairment charge of $6.6M on IPR&D asset after discontinuing an immuno-inflammatory drug candidate.","Positive Phase 2b top-line for ATI-1777 in atopic dermatitis; seeking a partner for development/commercialization.","Co-founder Dr. Neal Walker returns as Interim CEO; company to advance zunsemetinib in oncology via Washington University trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":31249000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244377,"accession_number":"0001558370-24-000769","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aclaris terminates CMO, enters separation with former CEO; promotes CSO to full-time","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terminated Gail Cawkwell as CMO effective Jan 31, 2024, without cause; receives 12-month salary continuation and COBRA coverage.","Entered separation agreement with former CEO Douglas Manion on Feb 4, 2024; receives 12-month salary continuation plus unpaid 2023 bonus.","Amended CSO Joseph Monahan's employment; base salary raised to $430,000, moves from part-time to full-time effective Feb 1, 2024.","Monahan’s new agreement has a 2-year initial term with automatic one-year renewals unless 90-day notice is given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244375,"accession_number":"0001558370-24-000770","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K/A","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aclaris discloses interim CEO Neal Walker's compensation: $500k salary, equity awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Manion stepped down as CEO/President effective Jan 16, 2024; no disagreement.","Neal Walker appointed Interim CEO; receives $500,000 base salary, bonus eligible at 60% of base.","Granted stock option for 497,000 shares at $1.20 per share, vesting monthly over 15 months.","Also granted RSU for 142,000 shares with same 15-month monthly vesting and change-in-control acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244376,"accession_number":"0001558370-24-000373","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Aclaris Therapeutics CEO Douglas Manion steps down; Neal Walker named interim CEO; strategic review launched","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Manion stepped down as CEO/President and Board member effective Jan 16, 2024; mutual decision with no disagreement.","Chairman and co-founder Neal Walker appointed interim CEO effective Jan 17, 2024; previously served as CEO until 2022.","Company initiates strategic review to maximize shareholder return; no timeline or definitive course set.","Preliminary unaudited cash, cash equivalents and marketable securities ~$182M as of Dec 31, 2023.","Seeking partner for ATI-1777; assessing pathway for ATI-2138; discovery programs continue via KINect platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261806,"accession_number":"0001558370-23-019911","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Aclaris cuts workforce 46%, expects ATI-1777 Phase 2b topline data in Jan 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~46%; one-time charge ~$3.1M in Q4 2023, total costs $5.0-5.3M over 12 months.","ATI-1777 Phase 2a results published in JID Innovations; Phase 2b topline data expected January 2024.","ATI-450 (zunsemetinib) repurposed for pancreatic cancer and metastatic breast cancer in collaboration with Washington University.","ATI-2138 (ITK/JAK3) indication reassessed due to competitive landscape; guidance in early 2024.","Company accelerating discovery programs from KINect platform to generate IND applications near term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261805,"accession_number":"0001558370-23-018691","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aclaris Phase 2b zunsemetinib fails endpoints; ATI-450 program discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study of oral MK2 inhibitor zunsemetinib (20mg or 50mg BID) in 251 RA patients did not meet primary endpoint ACR20 at week 12.","No differentiation from placebo on secondary endpoints (ACR50, ACR70, DAS28-CRP); no meaningful safety findings.","Aclaris discontinues ATI-450 development; halts enrollment in Phase 2a psoriatic arthritis trial.","Phase 2b results for ATI-1777 (topical JAK1/3) in atopic dermatitis expected year-end 2023; Phase 2 for ATI-2138 planned early 2024.","Cash, cash equivalents and marketable securities of $187.0M as of Sep 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261804,"accession_number":"0001558370-23-017655","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q3 net loss $29.3M, revenue $9.3M; zunsemetinib RA data due Nov 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.3M for Q3 2023 compared to $20.0M in Q3 2022.","Total revenue $9.3M, down from $19.0M due to prior year Lilly payment.","Cash and securities $187.0M as of Sept 30, 2023; sufficient through end of 2025.","Zunsemetinib Phase 2b RA topline data expected November 2023.","ATI-1777 Phase 2b AD data expected around year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":13679000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278986,"accession_number":"0001558370-23-015840","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris reports positive Phase 1 MAD data for ATI-2138; advances to Phase 2a in ulcerative colitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATI-2138 well tolerated in 60-subject MAD trial; no serious adverse events; mild headache and diarrhea only events in >1 subject.","Dose-proportional PK and near-maximal inhibition of ITK and JAK3 biomarkers achieved at 30 mg total daily dose.","Company to start Phase 2a proof-of-concept in ulcerative colitis in early 2024; evaluating second PoC in another T-cell mediated disease.","CEO highlights KINect discovery engine; upcoming Phase 2 data for zunsemetinib (RA) and ATI-1777 (atopic dermatitis) expected late 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278985,"accession_number":"0001558370-23-013487","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q2 net loss widens to $29.6M; zunsemetinib RA data expected Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.6M vs $20.5M YoY; revenue $1.9M vs $1.5M, driven by licensing royalties.","Cash $210.8M, sufficient through 2025; includes $26.7M from ATM share sale in April 2023.","Zunsemetinib Phase 2b RA trial enrollment completed; topline data expected Q4 2023.","ATI-2138 Phase 1 MAD completed in healthy volunteers; data expected September 2023.","G&A expenses $8.3M include bad debt from EPI Health bankruptcy filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":4397000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297312,"accession_number":"0001558370-23-010987","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aclaris CSO Joseph Monahan shifts to part-time; base salary reduced to $280,800","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Monahan will serve as Chief Scientific Officer at 60% of full-time schedule as of July 1, 2023.","Annual base salary reduced to $280,800; annual bonus eligibility pro-rated for part-time service.","Amended employment agreement has initial two-year term with automatic one-year renewals unless 90-day notice given.","Monahan remains in role; prior agreement superseded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297311,"accession_number":"0001558370-23-010763","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aclaris stockholders approve doubling of authorized shares to 200M at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to authorized common stock from 100M to 200M shares approved: 60.7M for, 547K against, 3.4M abstain.","All three director nominees elected: Mehra 58.4M for, Powell 39.3M for, Gowen 57.3M for (Powell had 20.6M withheld).","Advisory say-on-pay approved: 58.6M for, 1.2M against, 28K abstain.","Ratification of PwC as auditor approved: 64.7M for, 16K against, 13K abstain.","Meeting turnout: 91.56% of 70.7M outstanding shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297310,"accession_number":"0001558370-23-010719","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclaris Therapeutics signs new HQ lease for 11,564 sq ft in Wayne, PA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with CBCC – Lee Road Acquisitions for space at 701 Lee Road, Wayne, PA.","Term expected to start Nov 1, 2023, expire March 31, 2029; one five-year extension option.","Base rent initial $30,114.58/month after 4-month abatement; escalates 2.5% annually.","Premises is 11,564 rentable square feet; Tenant pays pro rata share of operating expenses and taxes.","Lease includes early access for furniture and fixtures, standard default and subordination provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297309,"accession_number":"0001558370-23-008380","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aclaris posts Q1 net loss of $28.2M; delays PsA and AD trial data timelines","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $28.2M from $18.8M YoY; revenue rose to $2.5M on higher licensing royalties.","Cash, cash equivalents and marketable securities $204.4M; ATM raised $26.7M net in April, extending runway through end-2025.","Zunsemetinib RA Phase 2b data guided to Q4 2023; PsA Phase 2a data delayed to H1 2024 (from YE 2023) due to slow European enrollment.","ATI-1777 AD Phase 2b data now expected H2 2023 (from mid-year) after protocol expansion to include milder disease.","ATI-2138 MAD data on track for H2 2023; ulcerative colitis selected as first development target."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":2528000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297308,"accession_number":"0001558370-23-005917","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris updates corporate presentation; no specific financial or pipeline news disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished an updated corporate overview presentation on April 14, 2023.","Presentation titled 'Empowering Patients Through Kinome Innovation' emphasizes kinase-focused pipeline.","No material new data on drug candidates, financials, or regulatory milestones in the disclosed exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317665,"accession_number":"0001104659-23-040192","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Aclaris raises $27.5M via sale of 3.4M shares to Bain Capital affiliates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3.4M shares of common stock for aggregate gross proceeds of $27.5M.","Shares purchased by entities affiliated with Bain Capital Life Sciences.","Sale executed under existing ATM agreement with SVB Securities and Cantor Fitzgerald."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317664,"accession_number":"0001558370-23-004698","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aclaris extends former CFO Frank Ruffo's consulting term to June 30, 2023 with $12,500 monthly fee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Consulting term extended from March 3, 2023 through June 30, 2023.","Monthly consulting fee set at $12,500 for services rendered during the term.","No outstanding equity awards will vest after March 2, 2023; vesting ceased on that date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317663,"accession_number":"0001558370-23-002835","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aclaris Phase 2a zunsemetinib trial for hidradenitis suppurativa fails to meet endpoints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study did not meet primary endpoint of change in inflammatory nodule/abscess count at week 12.","Secondary endpoints including HiSCR-50 also not met; placebo effect higher than in published HS studies.","Zunsemetinib generally well tolerated; most common AEs: dizziness (16.7%), diarrhea (12.5%), headache (12.5%).","No serious adverse events or opportunistic infections observed; PK/PD consistent with prior studies.","CEO notes next data readout from Phase 2b rheumatoid arthritis study is expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317662,"accession_number":"0001558370-23-001826","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aclaris Q4 net loss $27.6M; revenue $7.8M on licensing; cash $229.8M through 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $27.6M vs $22.8M in Q4 2021; full-year net loss $86.9M vs $90.9M.","Q4 total revenue $7.8M (incl. $6.7M licensing, $5M from Pediatrix) vs $1.5M prior year.","Cash, equivalents and marketable securities $229.8M; expected to fund operations through end of 2025.","Phase 2a zunsemetinib HS topline data expected March 2023; Phase 2b RA data H2 2023.","Phase 2b ATI-1777 atopic dermatitis topline data mid-2023; Phase 1 MAD ATI-2138 data H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":29752000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317661,"accession_number":"0001104659-23-024751","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Aclaris Therapeutics enters $200M ATM equity facility, terminates prior $150M ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with SVB Securities and Cantor Fitzgerald for up to $200M in common stock at-the-market.","Prior $150M ATM terminated; $72.7M net proceeds raised from 4.8M shares under prior agreement.","Commission of 3% of gross proceeds on sales under new agreement.","Company not obligated to sell any shares; offering at its sole discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317660,"accession_number":"0001558370-23-000121","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclaris presents at J.P. Morgan Healthcare Conference on Jan 11; no material financial updates","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management presents company overview and slide deck at 41st Annual J.P. Morgan Healthcare Conference on Jan 11, 2023.","Presentation focuses on Aclaris' kinome innovation platform; no specific product or pipeline data disclosed.","No financial guidance, clinical trial results, or material corporate developments included in the filing.","Filing is a procedural disclosure under Regulation FD; exhibit contains only cover slide with no substantive new information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317659,"accession_number":"0001104659-23-001858","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aclaris finalizes CEO and CFO employment agreements; Manion $600k base, Balthaser $444k base","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Manion appointed CEO effective Jan 1, 2023 with annual base salary of $600,000 and target bonus of 55% of base.","Kevin Balthaser appointed CFO effective Jan 1, 2023 with annual base salary of $444,000 and target bonus of 40% of base.","Both employment agreements have initial two-year term with automatic renewal; severance includes 12-month base salary and COBRA in non-change-of-control terminations.","Under change of control termination, Manion receives additional 6 months salary and 150% target bonus; Balthaser receives additional target bonus; both get full equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335915,"accession_number":"0001104659-22-126640","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aclaris Therapeutics enters separation agreement with retiring executive Frank Ruffo","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frank Ruffo's retirement separation agreement approved; includes consulting deal through March 2, 2023 for $25,000.","Ruffo will continue vesting of outstanding options and RSUs during the consulting period.","Exercise period for vested options extended to December 31, 2023.","Ruffo retains eligibility for 2022 annual bonus and accrued pay/vacation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335914,"accession_number":"0001104659-22-121225","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2022-11-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aclaris Therapeutics CEO Neal Walker to step down, becomes Chair; CFO Ruffo retires; Manion named CEO, Balthaser CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neal Walker resigns as CEO effective Dec 31, 2022; appointed Chair of the Board effective Jan 1, 2023.","CFO Frank Ruffo retires effective Dec 31, 2022; will serve as consultant through March 2, 2023.","Douglas Manion, currently President, appointed CEO and Class I Director effective Jan 1, 2023.","Kevin Balthaser, VP Finance since 2022, appointed CFO effective Jan 1, 2023.","Christopher Molineaux becomes Lead Independent Director effective Jan 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335913,"accession_number":"0001558370-22-016735","cik":1557746,"company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aclaris Q3 net loss $20M, revenue $19M on $17.6M Lilly license; ATI-2138 Phase 1 SAD positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.0M for Q3 2022 vs $21.1M in Q3 2021; operating loss offset by $17.6M licensing revenue from Lilly alopecia areata patent deal.","Total revenue of $19.0M, up from $1.7M year-over-year, driven by $17.9M licensing revenue.","Cash, equivalents and marketable securities of $248.1M as of Sep 30, 2022; sufficient to fund operations through end of 2025.","Phase 2a enrollment completed for zunsemetinib in hidradenitis suppurativa (95 patients); topline data expected mid-first half 2023.","ATI-2138 Phase 1 SAD trial completed; generally well-tolerated, dose-dependent ITK/JAK3 inhibition; ulcerative colitis selected as first target; new IND submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":21999000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":637564692.8209608,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-08T23:59:59+00:00|335913"}